Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells

• DOI: 10.1038/s41467-017-00297-x
• Publication Date: 2017-07-28T09:54:32Z
• Authors: Jiajia Cui; Lingfeng Qin; Junwei Zhang; Parwiz Abrahimi; Hong Li; Guangxin Li; Gregory T. Tietjen; George Tellides; Jordan S. Pober; W. Mark Saltzman
• Keywords: Ex vivo

Human endothelial cells are initiators and targets of the rejection response. Pre-operative modification by small interfering RNA transfection could shape nature host response post-transplantation. Ablation cell class II major histocompatibility complex molecules targeting transactivator can reduce capacity human to recruit activate alloreactive T cells. Here, we report development RNA-releasing poly(amine-co-ester) nanoparticles, distinguished their high content a hydrophobic lactone. We show that single attenuates expression on for at least 4 6 weeks after transplantation into immunodeficient mouse hosts. Furthermore, silencing reduces allogeneic T-cell responses in vitro vivo. These data suggest potentially administered during ex vivo normothermic machine perfusion organs, be used modify with sustained effect transplantation.The use gene techniques treatment post-transplantation is not long lasting have systemic effects. authors utilize nanocarrier siRNA arteries prior implantation subsequently attenuating immune reaction